DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Tarella C, Passera R, Magni M. et al.
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
J Clin Oncol 2011;
29: 814-824
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.